Learning Objectives

1.     Recognize the incidence of childhood B cell acute lymphoblastic leukemia, total relapses, and CNS-specific relapses.

2.    Describe the history of treatment for upfront and relapsed CNS disease in acute lymphoblastic leukemia as well as its associated morbidities.

3.     Apply current accepted treatment(s) for CNS relapsed leukemia and recognize its potential shortcomings.

4.     Distinguish how CAR-T cell therapy is currently being used to treat relapsed/refractory acute lymphoblastic leukemia, specifically in CNS relapses.

5.    Appraise future possible applications, timeframes for introducing CAR-T cell therapy in treatment models for CNS-relapsed acute lymphoblastic leukemia.